NCT05199571 - Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 22, 2022

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions

Relapsing Multiple Sclerosis

Interventions

BIOLOGICAL

Ofatumumab

Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab

Trial Locations (18)

100034

Novartis Investigative Site, Beijing

110011

Novartis Investigative Site, Shenyang

150001

Novartis Investigative Site, Harbin

200025

Novartis Investigative Site, Shanghai

215004

Novartis Investigative Site, Suzhou

300052

Novartis Investigative Site, Tianjin

310006

Novartis Investigative Site, Hangzhou

430030

Novartis Investigative Site, Wuhan

510000

Novartis Investigative Site, Guangzhou

510080

Novartis Investigative Site, Guangzhou

510260

Novartis Investigative Site, Guangzhou

510630

Novartis Investigative Site, Guangzhou

518036

Novartis Investigative Site, Shenzhen

730030

Novartis Investigative Site, Lanzhou

830054

Novartis Investigative Site, Ürümqi

050000

Novartis Investigative Site, Shijiazhuang

030001

Novartis Investigative Site, Taiyuan

065001

Novartis Investigative Site, Beijing